Posaconazole for the Prevention of COVID-19 Associated Pulmonary Aspergillosis in Critically-Ill Patients: A European Multicenter Case-Control Study
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Posaconazole (Primary)
- Indications Aspergillosis
- Focus Therapeutic Use
- Acronyms POSACOVID
- 12 Mar 2024 Status changed from recruiting to completed.
- 08 Oct 2021 New trial record